Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to confirm the long-term efficacy (remission and maintenance in remission) of current validated treatments. Each patient will be followed during 3 years in this non-interventional trial.

Official Title
-----------------
Observatoire Prospectif, Longitudinal Dans la Prise en Charge Thérapeutique de La Rectocolite Hémorragique légère à Modérée

Conditions
-----------------
Ulcerative Colitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old or above Ulcerative colitis, whatever the extension, in mild to moderate flare-up (including proctitis) Having received the information sheet Exclusion Criteria: Participating, at the time of inclusion, in another study using an investigational drug or device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remission rate (ulcerative colitis) - calculated by UCCS (Ulcerative Colitis Clinical Score) |  | From baseline (inclusion visit) and at 1 year interval after baseline | 
| Remission rate (ulcerative colitis) - calculated by UCCS (Ulcerative Colitis Clinical Score) |  | From baseline (inclusion visit) and at 2 year interval after baseline | 
| Remission rate (ulcerative colitis) - calculated by UCCS (Ulcerative Colitis Clinical Score) |  | From baseline (inclusion visit) and at 3 year interval after baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remission rate (endoscopic) - calculated by UC-DAI (Ulcerative Colitis Disease Activity Index) |  | From baseline (inclusion visit) and at 1 year interval after baseline | 
| Assessing treatment adherence by patient's completion of questionnaire MMAS-8 (Modified Morisky Adherence Scale) |  | From baseline (inclusion visit) and at 1 year interval after baseline | 
| Occurence/number of adverse events |  | From baseline (inclusion visit) to year 3 after baseline | 
| Colonoscopy (if available) - assessing endoscopic activity of the ulcerative colitis |  | From baseline (inclusion visit) to 3 year after baseline | 
| Remission rate (endoscopic) - calculated by UC-DAI (Ulcerative Colitis Disease Activity Index) |  | From baseline (inclusion visit) and at 2 year interval after baseline | 
| Remission rate (endoscopic) - calculated by UC-DAI (Ulcerative Colitis Disease Activity Index) |  | From baseline (inclusion visit) and at 3 year interval after baseline | 
| Assessing treatment adherence by patient's completion of questionnaire MMAS-8 (Modified Morisky Adherence Scale) |  | From baseline (inclusion visit) and at 2 year interval after baseline | 
| Assessing treatment adherence by patient's completion of questionnaire MMAS-8 (Modified Morisky Adherence Scale) |  | From baseline (inclusion visit) and at 3 year interval after baseline |